Search 33,000+ CME courses
Back

StatPearls, LLC

  • Acitretin
  • Bowen's Disease
  • Carcinoma, Squamous Cell
  • Epidermodysplasia Verruciformis
  • Imiquimod

Epidermodysplasia Verruciformis

Epidermodysplasia verruciformis is a rare genetic dermatological condition characterized by a compromised immune ability to defend against and eliminate certain types of human papillomavirus (HPV). This leads to persistent HPV infections and a significantly increased lifetime risk of developing cutaneous dysplasia and malignancy. Individuals with this condition develop HPV-derived cutaneous lesions at a significantly higher rate than the general population. This genodermatosis primarily manifests as verrucous cutaneous lesions, including multiple persistent verrucae, pityriasis versicolor-like lesions, and other verrucous or “warty” lesions. This can also lead to the development of Bowen disease and squamous cell carcinoma. The lesions associated with epidermodysplasia verruciformis tend to exhibit a characteristic histopathologic appearance. No definitive treatment exists for epidermodysplasia verruciformis. However, several potential options are recommended, including excision, acitretin, imiquimod, interferons with retinoids, and topical calcipotriol. The efficacy of cimetidine is debated. As the lesions commonly occur in sun-exposed areas, counseling on sun protection and adherence to preventive measures are essential for managing the condition. This activity reviews the epidemiology, genetics, clinical presentation, and management of epidermodysplasia verruciformis, providing insights into current and emerging treatment options, including antiviral therapies, immunomodulators, and surgical interventions. This activity also highlights the role of an interprofessional healthcare team in improving patient care through regular monitoring and early intervention to manage complications and reduce cancer risk.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1 creditAAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABS — Accredited CMEUp to 1 pointABPATH — Lifelong LearningUp to 1 pointABTS — Accredited CMEUp to 1 pointABIM — Medical KnowledgeUp to 1 pointABS — Self-AssessmentUp to 1 pointABP — Lifelong Learning and Self-AssessmentUp to 1 pointABTS — Self-AssessmentUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left

More from StatPearls, LLC

See all

This provider’s courses closest to this one